Stanford, CA, United States of America

Susan Rodriguez

This inventor holds 1 USPTO granted patent. Top assignee: Alza Corporation. Active years: 1999.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 345(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Susan Rodriguez

Introduction

Susan Rodriguez is a notable inventor based in Stanford, CA. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions that include opioid antagonists. Her work is crucial in addressing the challenges associated with opioid analgesics.

Latest Patents

Susan Rodriguez holds 1 patent for her invention titled "Composition and dosage form comprising opioid antagonist." This patent discloses a composition of matter that includes an opioid antagonist combined with a high molecular weight poly(alkylene) or poly(carboxymethylcellulose). The dosage form is designed to effectively displace an opioid analgesic from the dosage form, showcasing her innovative approach to drug formulation.

Career Highlights

Throughout her career, Susan has been associated with Alza Corporation, where she has contributed her expertise in pharmaceutical sciences. Her work has been instrumental in advancing the development of safer and more effective medication options.

Collaborations

Susan has collaborated with esteemed colleagues such as Anthony L Kuczynski and Jerry D Childers. These partnerships have fostered a collaborative environment that enhances innovation and research in the pharmaceutical industry.

Conclusion

Susan Rodriguez exemplifies the spirit of innovation in the pharmaceutical field through her groundbreaking work on opioid antagonists. Her contributions are vital in the ongoing efforts to improve drug safety and efficacy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…